

## CERTIFICATE OF FACSIMILE TRANSMITTAL

Facsimile Number (703) 308-4242 Date of Transmission 1/27/03

I hereby certify that this correspondence (and all other documents mentioned therein) is being transmitted by facsimile to the Assistant Commissioner for Patents, Washington, D.C. 20231, to the above facsimile number on the above-date

Helena Beckman  
Helena Beckman

FAX RECEIVED

JAN 28 2003

Docket: ONYX1028-DIV

OFFICIAL GROUP 1600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## In re Application

Gideon Bollag et al

Examiner: W. Sandals

SC/Serial No.: 10/054,435

Art Unit: 1636

Filed: January 18, 2002

Title: Methods and Compositions for Treating  
Abnormal Cell Growth Related to  
Unwanted Guanine Nucleotide  
Exchange Factor Activity

RESPONSE TO OFFICE ACTION UNDER 35 U.S.C. §121

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

Responsive to the Office Action mailed December 24, 2002, setting forth a Restriction Requirement, Applicants elect without traverse, those claims in Group 1, Claims 1-6, drawn to a RAC-GEF polypeptide, classified in class 530, subclass 350.

Applicants hereby request a 1-Month Extension of Time to submit this Response. A Petition for a One-Month Extension of Time is being filed along with this Response.

Atty Docket ONYX1028-DIV  
Serial No. 10/054,435

2

The Commissioner is hereby authorized to charge any fees associated with this communication to Deposit Account No. 15-0615.

Respectfully submitted,

Date: 1/27/03

By: Gregory Giotta  
Gregory Giotta  
Reg. No. 32,028

ONYX Pharmaceuticals, Inc.  
3031 Research Drive  
Richmond, California 94806  
Telephone (510) 222-9700  
Facsimile (510) 22209758